Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Meeting Abstract

    Li, Q.; Razavi, P.; Li, Z.; Da Cruz Paula, A. F.; Brogi, E.; Scaltriti, M.; Reis, J. S.; Chandarlapaty, S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
    Meeting Abstract

    Takahashi, S.; Modi, S.; Tsurutani, J.; Krop, I. E.; Iwata, H.; Wada, R.; Yin, O.; Garimella, T.; Sugihara, M.; Zhang, L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Prevalence and preliminary validation of screening criteria to identify carriers of germline BAP1 mutations
    Journal Article

    Zauderer, M. G.; Jayakumaran, G.; DuBoff, M.; Zhang, L.; Francis, J. H.; Abramson, D. H.; Cercek, A.; Nash, G. M.; Shoushtari, A.; Chapman, P.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • A small-molecule pan-Id antagonist inhibits pathologic ocular neovascularization
    Journal Article

    Wojnarowicz, P. M.; Lima e Silva, R.; Ohnaka, M.; Lee, S. B.; Chin, Y.; Kulukian, A.; Chang, S. H.; Desai, B.; Garcia Escolano, M.; Shah, R.; more...
    Cell Reports (2019)

    Fulltext@MSK | Save
  • Mammographic screening in male patients at high risk for breast cancer: Is it worth it?
    Journal Article

    Marino, M. A.; Gucalp, A.; Leithner, D.; Keating, D.; Avendano, D.; Bernard-Davila, B.; Morris, E. A.; Pinker, K.; Jochelson, M. S.
    Breast Cancer Research and Treatment (2019)

    Fulltext@MSK | Save
  • Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
    Journal Article

    Osmanbeyoglu, H. U.; Shimizu, F.; Rynne-Vidal, A.; Alonso-Curbelo, D.; Chen, H. A.; Wen, H. Y.; Yeung, T. L.; Jelinic, P.; Razavi, P.; Lowe, S. W.; more...
    Nature Communications (2019)

    Fulltext@MSK | Save
  • Association of a pathway-specific genetic risk score with risk of radiation-associated contralateral breast cancer
    Journal Article

    Watt, G. P.; Reiner, A. S.; Smith, S. A.; Stram, D. O.; Capanu, M.; Malone, K. E.; Lynch, C. F.; John, E. M.; Knight, J. A.; Mellemkjær, L.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: Protocol for a mixed-methods randomised controlled trial
    Journal Article

    Shickh, S.; Clausen, M.; Mighton, C.; Gutierrez Salazar, M.; Zakoor, K. R.; Kodida, R.; Reble, E.; Elser, C.; Eisen, A.; Panchal, S.; more...
    BMJ Open (2019)

    Fulltext@MSK | Save
  • A pilot study of stereotactic body radiotherapy (SBRT) combined with a PD-L1 antibody durvalumab (D) and a CTLA-4 antibody tremelimumab (T) to treat metastatic anaplastic thyroid cancer (ATC)
    Meeting Abstract

    Lee, N.; Tsai, C. J.; Riaz, N.; Wu, V.; Brinkman, T.; Zhi, W.; Fetten, J.; Ho, A.; Pfister, D. G.; Sherman, E.
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save